The Basics of HPLC Peptide Analysis

December 10, 2019
LCGC’s CHROMacademy

The Column

The Column, The Column-12-10-2019, Volume 15, Issue 12
Page Number: 31–32

To fully characterize a protein biopharmaceutical, it must be broken down into smaller segments (peptides). Several high performance liquid chromatography (HPLC) techniques can be used to provide a wealth of information on everything from post-translational modifications (PTMs) to the glycoprofile to information on similarity when characterizing biosimilars.

To fully characterize a protein biopharmaceutical, it must be broken down into smaller segments (peptides). Several high performance liquid chromatography (HPLC) techniques can be used to provide a wealth of information on everything from post-translational modifications (PTMs) to the glycoprofile to information on similarity when characterizing biosimilars.

Much information is available when biomolecules are analyzed at the protein level, such as molecular weight, structural integrity, charge variants, aggregation, and post‑translational modifications (PTMs). However, identification of PTM modification sites, as well as other critical quality attributes such as the glycoprofile, requires digesting the protein into representative peptides using a suitable proteolytic digestion enzyme.

The digested peptide-containing solution is then chromatographed, commonly using a generic reversed-phase liquid chromatography (LC) methodology that consists of an acidic mobile phase, a steeper gradient over a wider range, and a longer alkyl chain stationary phase (such as C18, for example) as compared to the method employed to analyze an intact protein.

A typical peptide map of a digested monoclonal antibody (mAb) is shown in Figure 1. It is considerably more complex than those generated for intact proteins because of the number of peptides liberated and the artifacts that arise from the digestion process, such as residual reagents and missed cleavages.

Great care and consideration are required during the digestion process, as the proteolytic enzymes used and the conditions employed (pH, temperature, even storage time) not only affect the overall number of peptides liberated but also the stability of associated PTMs, and can even introduce protein modifications of their own.

 

Broadly speaking, the digestion process can be broken down into three separate steps: reduction, alkylation, and digestion.

The first stage in the reduction step is to denature the mAb. This is commonly accomplished with an acid-labile surfactant that removes the higher order structure of the protein and exposes many otherwise internal disulfide bonds. These disulfide bonds are then ready for reduction, which is achieved using dithiothreitol. The pH is maintained at physiological levels throughout the process using buffers. To prevent reformation of disulfide bridges across the thiol groups of the cysteine (C) residues, the protein is then incubated with an alkylating agent such as 2-iodoacetamide, once again at physiological pH. The final stage is the addition of a proteolytic agent capable of site-specific protein digestion. Table 1 details these enzymes and highlights their specific cleavage sites. Typically, fewer cleavage sites leads to larger and, therefore, fewer resulting peptides, and vice versa.

Due to the precise and predictable nature of the hydrophobic retention of reversed‑phase LC, estimates as to where the modified peptide will elute in relation to the native, unmodified variant can be made (Table 2). This can be a helpful tool when trying to identify and assign unexpected peaks. Asparagine deamidation can produce both pre- and post-peaks, due to deamidation occurring via the succinimide intermediate, iso-Asp (pre‑peak), and Asp (post-peak) in a 3/4:1 ratio.